Mark Plante

About

Dr. Mark Plante is a leading urologic surgeon whose research has fundamentally advanced the treatment of benign prostatic hyperplasia (BPH), particularly for patients with large-volume prostates. His work centers on the development and validation of Aquablation therapy, a minimally invasive robotic surgery that uses a high-velocity water jet to precisely remove obstructing prostate tissue. Dr. Plante’s landmark contributions include authoring the pivotal 1-year and 2-year results of the WATER II clinical trial, which demonstrated the safety and efficacy of Aquablation for prostates sized 80-150 cc. His most cited paper (63 citations) established the procedure’s viability for these challenging cases, while his 5-year follow-up study (49 citations) confirmed durable symptom relief and low retreatment rates. Notably, his subgroup analysis from a blinded randomized trial (42 citations) showed that Aquablation significantly reduces the risk of anejaculation compared to traditional transurethral resection of the prostate (TURP), a critical quality-of-life benefit. Through these high-impact studies, Dr. Plante has helped position Aquablation as a transformative alternative for men with large prostates, offering effective relief with fewer sexual side effects.

Research Focus

Key Achievements

Top Papers

1. 1
   Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results

   63 citations · 2019
2. 2
   Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results

   49 citations · 2023
3. 3
   Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial

   42 citations · 2018
4. 4
   Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results.

   24 citations · 2020

Key Collaborators

Contact & Links